Blackstone Life Sciences Deal History & Licensing Activity
Blackstone Life Sciences is a large biotech. Over the past three years, Blackstone Life Sciences has been involved in 3 licensing and acquisition transactions, with a primary focus on Oligonucleotides (2 deals).
Deals (12mo)
2
Active Trials
0
Top Modality
Oligonucleotides
Focus Area
Cardiovascular
Blackstone Life Sciences Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Blackstone Life Sciences in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| RNAi pipeline | Alnylam | Oligonucleotides | Unknown | collaboration | May 18, 2026 |
Blackstone Life Sciences Pipeline Focus
Therapeutic areas and modalities where Blackstone Life Sciences is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
See How Your Asset Matches Blackstone Life Sciences's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Cardiovascular assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Cardiovascular Deal Benchmarks
Market sizing, deal terms, and competitive landscape for cardiovascular
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
mRNA Benchmarks
Upfront, milestone, and royalty benchmarks for mrna deals
About Blackstone Life Sciences Licensing & Deal Activity
Blackstone Life Sciences is a large biotech company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Blackstone Life Sciences ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Blackstone Life Sciences include Cardiovascular (2 deals and trials), Infectious Disease (1 deal and trial), and Gastroenterology (1 deal and trial). In terms of modality, Blackstone Life Sciences has shown particular interest in oligonucleotides, mrna, antibodies.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Blackstone Life Sciences and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Blackstone Life Sciences's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.